To view this email as a web page, click here

Today's Rundown

Featured Story

Trump administration pushes for healthcare facilities to reopen

Healthcare facilities in states that have seen enough of a decline in COVID-19 cases to reach the Phase II criteria for reopening their economies should begin offering nonemergent, non-COVID-19 care, the Trump administration said Monday.

read more

Top Stories

Bristol Myers CEO Caforio on coronavirus R&D: Let's make it a 'new standard for collaboration'

Bristol Myers Squibb CEO Giovanni Caforio has been watching Operation Warp Speed and other efforts to end the COVID-19 pandemic play out, and now he has a message for his Big Pharma peers. Speed matters, but not as much as reaping the benefits of working together to address unmet medical needs, he said.

read more

Illumina debuts next-gen sequencing test for COVID-19

Illumina received an emergency authorization from the FDA for its COVID-19 test designed to sequence the full genome of the novel coronavirus.

read more

Cigna: COVID-19 leading to deferred pediatric care for conditions like epilepsy, asthma

COVID-19 is leading many parents to defer acute care for their children, new data from Cigna show.

read more

Moderna, AstraZeneca and J&J coronavirus shots rev up for NIH tests beginning in July: WSJ

As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to run phase 3 trials of vaccines from Moderna, AstraZeneca and Johnson & Johnson in the coming months, the Wall Street Journal reports.

read more

Decoding COVID-19's Achilles' heel to inspire new treatments

A new study from the University of Zaragoza in Spain has found what could be SARS-CoV-2’s Achilles’ heel—a protein that’s critical for the reproduction of the virus. The researchers argue it could make an excellent target for potential inhibitors of the virus.

read more

Biopharma roundup—AZ, J&J and Moderna shots aim for phase 3; Industry leaders talk post-pandemic growth at BIO conference

The NIH rolled out plans to move COVID vaccines from AZ, Moderna and J&J into phase 3 testing over the summer, while WHO updated its list of candidate shots. Cue Health will invest in manufacturing space to make COVID tests. Plus, Industry leaders discussed lessons learned from the pandemic at a BIO panel.

read more

UnitedHealth execs: Patients are using telehealth for convenience, not as a necessity

Telehealth use began to skyrocket back in March as patients saw virtual care as a necessity amid the COVID-19 pandemic. Patients are continuing to see doctors over video visits, but for different reasons now—it's more convenient and faster than going to see the doctor in person. Find out why OptumHealth CEO Wyatt Decker sees this as a dramatic shift that points to the future of telehealth.

read more

BIO: Exploring COVID-19's opportunities for AI, regulatory flexibility and 'handshake' deals

The challenges posed by the novel coronavirus are also providing new openings for rapid advancement in the life sciences field—especially in the adoption of big data and artificial intelligence, as companies look toward partnerships to tackle each scientific problem as fast and efficiently as possible, according to a panel of industry leaders at BIO’s virtual meeting.

read more

CVS maintains 2020 earnings guidance despite COVID-19 concerns

CVS Health is sticking with its 2020 earnings guidance, the healthcare giant said in an SEC filing this week.

read more

Cue Health raises $100M to boost portable coronavirus test development

Portable testing company Cue Health has raised $100 million in new venture capital funding shortly after acquiring a U.S. government contract to develop a rapid, point-of-care coronavirus diagnostic.

read more